A Newcastle Disease Virus (NDV) Expressing a Membrane-Anchored Spike as a Cost-Effective Inactivated SARS-CoV-2 Vaccine
Weina Sun, Stephen McCroskery, Wen-Chun Liu, Sarah R Leist, Yonghong Liu, Randy A Albrecht, Stefan Slamanig, Justine Oliva, Fatima Amanat, Alexandra Schäfer, Kenneth H Dinnon 3rd, Bruce L Innis, Adolfo García-Sastre, Florian Krammer, Ralph S Baric, Peter Palese, Weina Sun, Stephen McCroskery, Wen-Chun Liu, Sarah R Leist, Yonghong Liu, Randy A Albrecht, Stefan Slamanig, Justine Oliva, Fatima Amanat, Alexandra Schäfer, Kenneth H Dinnon 3rd, Bruce L Innis, Adolfo García-Sastre, Florian Krammer, Ralph S Baric, Peter Palese
Abstract
A successful severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine must not only be safe and protective, but must also meet the demand on a global scale at a low cost. Using the current influenza virus vaccine production capacity to manufacture an egg-based inactivated Newcastle disease virus (NDV)/SARS-CoV-2 vaccine would meet that challenge. Here, we report pre-clinical evaluations of an inactivated NDV chimera stably expressing the membrane-anchored form of the spike (NDV-S) as a potent coronavirus disease 2019 (COVID-19) vaccine in mice and hamsters. The inactivated NDV-S vaccine was immunogenic, inducing strong binding and/or neutralizing antibodies in both animal models. More importantly, the inactivated NDV-S vaccine protected animals from SARS-CoV-2 infections. In the presence of an adjuvant, antigen-sparing could be achieved, which would further reduce the cost while maintaining the protective efficacy of the vaccine.
Keywords: COVID-19; adjuvant; antigen-sparing; egg-based vaccine; hamster model; mouse-adapted SARS-CoV-2.
Conflict of interest statement
The Icahn School of Medicine at Mount Sinai has filed patent applications entitled “RECOMBINANT NEWCASTLE DISEASE VIRUS EXPRESSING SARS-COV-2 SPIKE PROTEIN AND USES THEREOF”.
Figures
References
- Jackson L.A., Anderson E.J., Rouphael N.G., Roberts P.C., Makhene M., Coler R.N., McCullough M.P., Chappell J.D., Denison M.R., Stevens L.J., et al. An mRNA Vaccine against SARS-CoV-2—Preliminary Report. N. Engl. J. Med. 2020;383:1920–1931. doi: 10.1056/NEJMoa2022483.
- Corbett K.S., Edwards D.K., Leist S.R., Abiona O.M., Boyoglu-Barnum S., Gillespie R.A., Himansu S., Schafer A., Ziwawo C.T., DiPiazza A.T., et al. SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature. 2020;586:567–571. doi: 10.1038/s41586-020-2622-0.
- Gao Q., Bao L., Mao H., Wang L., Xu K., Yang M., Li Y., Zhu L., Wang N., Lv Z., et al. Rapid development of an inactivated vaccine candidate for SARS-CoV-2. Science. 2020;369:77–81. doi: 10.1126/science.abc1932.
- Zhu F.C., Li Y.H., Guan X.H., Hou L.H., Wang W.J., Li J.X., Wu S.P., Wang B.S., Wang Z., Wang L., et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: A dose-escalation, open-label, non-randomised, first-in-human trial. Lancet. 2020;395:1845–1854. doi: 10.1016/S0140-6736(20)31208-3.
- DiNapoli J.M., Kotelkin A., Yang L., Elankumaran S., Murphy B.R., Samal S.K., Collins P.L., Bukreyev A. Newcastle disease virus, a host range-restricted virus, as a vaccine vector for intranasal immunization against emerging pathogens. Proc. Natl. Acad. Sci. USA. 2007;104:9788–9793. doi: 10.1073/pnas.0703584104.
- Liu R.Q., Ge J.Y., Wang J.L., Shao Y., Zhang H.L., Wang J.L., Wen Z.Y., Bu Z.G. Newcastle disease virus-based MERS-CoV candidate vaccine elicits high-level and lasting neutralizing antibodies in Bactrian camels. J. Integr. Agric. 2017;16:2264–2273. doi: 10.1016/S2095-3119(17)61660-5.
- Li K., Li Z., Wohlford-Lenane C., Meyerholz D.K., Channappanavar R., An D., Perlman S., McCray P.B., Jr., He B. Single-Dose, Intranasal Immunization with Recombinant Parainfluenza Virus 5 Expressing Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Spike Protein Protects Mice from Fatal MERS-CoV Infection. mBio. 2020;11:e00554-20. doi: 10.1128/mBio.00554-20.
- Liniger M., Zuniga A., Tamin A., Azzouz-Morin T.N., Knuchel M., Marty R.R., Wiegand M., Weibel S., Kelvin D., Rota P.A., et al. Induction of neutralising antibodies and cellular immune responses against SARS coronavirus by recombinant measles viruses. Vaccine. 2008;26:2164–2174. doi: 10.1016/j.vaccine.2008.01.057.
- Koch T., Dahlke C., Fathi A., Kupke A., Krahling V., Okba N.M.A., Halwe S., Rohde C., Eickmann M., Volz A., et al. Safety and immunogenicity of a modified vaccinia virus Ankara vector vaccine candidate for Middle East respiratory syndrome: An open-label, phase 1 trial. Lancet Infect. Dis. 2020;20:827–838. doi: 10.1016/S1473-3099(20)30248-6.
- Sun W., Leist S.R., McCroskery S., Liu Y., Slamanig S., Oliva J., Amanat F., Schaefer A., Dinnon K., Garcia-Sastre A., et al. Newcastle disease virus (NDV) expressing the spike protein of SARS-CoV-2 as vaccine candidate. EBioMedicine (Accepted) 2020 doi: 10.1016/j.ebiom.2020.103132.
- Vasievich E.A., Ramishetti S., Zhang Y., Huang L. Trp2 peptide vaccine adjuvanted with (R)-DOTAP inhibits tumor growth in an advanced melanoma model. Mol. Pharm. 2012;9:261–268. doi: 10.1021/mp200350n.
- Smalley Rumfield C., Pellom S.T., Morillon Ii Y.M., Schlom J., Jochems C. Immunomodulation to enhance the efficacy of an HPV therapeutic vaccine. J. Immunother. Cancer. 2020;8:e000612. doi: 10.1136/jitc-2020-000612.
- Riehl M., Harms M., Hanefeld A., Baleeiro R.B., Walden P., Mader K. Combining R-DOTAP and a particulate antigen delivery platform to trigger dendritic cell activation: Formulation development and in-vitro interaction studies. Int. J. Pharm. 2017;532:37–46. doi: 10.1016/j.ijpharm.2017.08.119.
- Gandhapudi S.K., Ward M., Bush J.P.C., Bedu-Addo F., Conn G., Woodward J.G. Antigen Priming with Enantiospecific Cationic Lipid Nanoparticles Induces Potent Antitumor CTL Responses through Novel Induction of a Type I IFN Response. J. Immunol. 2019;202:3524–3536. doi: 10.4049/jimmunol.1801634.
- Langley J.M., Wang L., Aggarwal N., Bueso A., Chandrasekaran V., Cousin L., Halperin S.A., Li P., Liu A., McNeil S., et al. Immunogenicity and Reactogenicity of an Inactivated Quadrivalent Influenza Vaccine Administered Intramuscularly to Children 6 to 35 Months of Age in 2012–2013: A Randomized, Double-Blind, Controlled, Multicenter, Multicountry, Clinical Trial. J. Pediatr. Infect. Dis Soc. 2015;4:242–251. doi: 10.1093/jpids/piu098.
- Madan A., Ferguson M., Rheault P., Seiden D., Toma A., Friel D., Soni J., Li P., Innis B.L., Schuind A. Immunogenicity and safety of an AS03-adjuvanted H7N1 vaccine in adults 65years of age and older: A phase II, observer-blind, randomized, controlled trial. Vaccine. 2017;35:1865–1872. doi: 10.1016/j.vaccine.2017.02.057.
- Wang L., Chandrasekaran V., Domachowske J.B., Li P., Innis B.L., Jain V.K. Immunogenicity and Safety of an Inactivated Quadrivalent Influenza Vaccine in US Children 6-35 Months of Age During 2013–2014: Results From A Phase II Randomized Trial. J. Pediatr. Infect. Dis. Soc. 2016;5:170–179. doi: 10.1093/jpids/piv041.
- Arifin M.A., Mel M., Abdul Karim M.I., Ideris A. Production of Newcastle disease virus by Vero cells grown on cytodex 1 microcarriers in a 2-litre stirred tank bioreactor. J. Biomed. Biotechnol. 2010;2010:586363. doi: 10.1155/2010/586363.
- Amanat F., Stadlbauer D., Strohmeier S., Nguyen T.H.O., Chromikova V., McMahon M., Jiang K., Arunkumar G.A., Jurczyszak D., Polanco J., et al. A serological assay to detect SARS-CoV-2 seroconversion in humans. Nat. Med. 2020;26:1033–1036. doi: 10.1038/s41591-020-0913-5.
- Vijayakumar G., Zamarin D. Design and Production of Newcastle Disease Virus for Intratumoral Immunomodulation. Methods Mol. Biol. 2020;2058:133–154.
- Dinnon K.H., 3rd, Leist S.R., Schafer A., Edwards C.E., Martinez D.R., Montgomery S.A., West A., Yount B.L., Jr., Hou Y.J., Adams L.E., et al. A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures. Nature. 2020;586:560–566. doi: 10.1038/s41586-020-2708-8.
- Amanat F., White K.M., Miorin L., Strohmeier S., McMahon M., Meade P., Liu W.C., Albrecht R.A., Simon V., Martinez-Sobrido L., et al. An In Vitro Microneutralization Assay for SARS-CoV-2 Serology and Drug Screening. Curr. Protoc. Microbiol. 2020;58:e108. doi: 10.1002/cpmc.108.
- Ania Wajnberg F.A., Firpo A., Altman D., Bailey M., Mansour M., McMahon M., Meade P., Mendu D.R., Muellers K., Stadlbauer D., et al. SARS-CoV-2 infection induces robust, neutralizing antibody responses that are stable for at least three months. medRxiv. 2020 doi: 10.1101/2020.07.14.20151126.
- Imai M., Iwatsuki-Horimoto K., Hatta M., Loeber S., Halfmann P.J., Nakajima N., Watanabe T., Ujie M., Takahashi K., Ito M., et al. Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development. Proc. Natl. Acad. Sci. USA. 2020;117:16587–16595. doi: 10.1073/pnas.2009799117.
- Chan J.F., Zhang A.J., Yuan S., Poon V.K., Chan C.C., Lee A.C., Chan W.M., Fan Z., Tsoi H.W., Wen L., et al. Simulation of the clinical and pathological manifestations of Coronavirus Disease 2019 (COVID-19) in golden Syrian hamster model: Implications for disease pathogenesis and transmissibility. Clin. Infect. Dis. 2020 doi: 10.1093/cid/ciaa644.
Source: PubMed